scFv Folding and Stability: Structural Determinants of Antigen Binding Single-chain variable fragments (scFvs) are widely used in antibody discovery, diagnostics, and therapeutic research because they combine a compact size with a complete antigen-binding site. However, their performance depends strongly on correct folding and stable association of the VH and VL domains. During recombinant expression or …
Polyclonal Antibody Purification Strategies for High Specificity and Reliable Performance Polyclonal antibodies (pAbs) recognize multiple epitopes on a target antigen, making them valuable tools for research, diagnostics, and therapeutic discovery. However, raw antiserum contains target-specific antibodies together with non-specific immunoglobulins and abundant serum proteins. A well-designed polyclonal antibody purification workflow is therefore essential for improving …
Fab Antibody Fragments: Advantages, Applications, and Limitations Fab antibody fragments are widely used in antibody engineering, therapeutics, and diagnostics because they retain antigen-binding activity while removing the Fc region of full-length IgG. At approximately 50 kDa, Fab fragments offer a useful balance between structural stability, tissue penetration, and production flexibility. Compared with IgG, scFv, and …
Hybridoma vs Phage Display: Choosing the Right Platform for Monoclonal Antibody Discovery Introduction Monoclonal antibody discovery relies mainly on two established platforms: hybridoma technology and display-based antibody selection, including phage display and yeast display. Both approaches have contributed significantly to research and therapeutic antibody development, but their advantages depend on target properties, project timelines, and …
Bispecific Antibodies Enable Safer Cancer Therapy Through Tumor-Selective Targeting Strategies Introduction Many cancer therapies fail to achieve their full potential because the molecular targets driving tumor growth are also essential for normal tissue function. Blocking pathways such as Wnt, EGFR, or FGFR1 can effectively inhibit tumors but often causes severe toxicity in healthy organs. A …
Optimizing scFv Linker Design to Improve Antibody Stability and Binding Performance Introduction Single-chain variable fragments (scFv antibodies) are widely used in antibody engineering due to their compact size, efficient expression, and compatibility with applications such as bispecific antibodies, CAR-T cell therapies, and fusion proteins. An scFv consists of VH and VL antibody domains connected by …
Downstream Purification Strategies for High-Quality VHH Antibody Production Introduction VHH antibodies, also known as nanobodies, are the smallest antibody fragments (~12–15 kDa) and have gained increasing attention due to their compact size, high stability, and ability to access unique epitopes. Following VHH discovery and VHH phage display screening, successful candidates require optimized expression and purification …
Somatic Mutations in Microglia Reveal a New Mechanism Driving Alzheimer’s Disease Progression Introduction Alzheimer’s disease (AD) is a complex neurodegenerative disorder traditionally associated with β-amyloid accumulation, Tau pathology, chronic inflammation, and neuronal loss. While microglia play a central role in regulating brain immune responses, the genetic mechanisms controlling their dysfunction remain poorly understood. A recent …
CAR-A for Alzheimer’s: A Breakthrough Neuro-Immunotherapy Using Engineered Astrocytes Introduction Alzheimer’s disease (AD) remains a major challenge, with current anti-Aβ monoclonal antibodies requiring high doses, repeated administration, and carrying risks like ARIA. A pioneering study in Science introduces CAR-A therapy—a next-generation neuro-immunotherapy that engineers astrocytes into super-phagocytes via Chimeric Antigen Receptors. This self-sustaining, one-time intervention …
Phage vs. Yeast Display: Why Eukaryotic Expression Wins for Antibody Developability In therapeutic antibody discovery, platform choice dictates downstream success. While phage display remains prized for its library size, yeast surface display—powered by eukaryotic expression—is rapidly becoming the industry standard for generating developable, manufacturable candidates. By leveraging Saccharomyces cerevisiae’s secretory machinery, yeast display ensures that selected …